Antibiotics Market Size, Share & Trends Report

Antibiotics Market Size, Share & Trends Analysis Report By Action Mechanism (Cell Wall Synthesis Inhibitors, RNA Synthesis Inhibitors), By Drug Class (Penicillin, Cephalosporin), By Type (Branded, Generic), And Segment Forecasts, 2024 - 2030

  • Report ID: GVR-1-68038-149-8
  • Number of Pages: 145
  • Format: Electronic (PDF)
  • Historical Range: 2018 - 2022
  • Industry: Healthcare

Research Methodology

A three-pronged approach was followed for deducing the antibiotics market estimates and forecasts. The process has three steps: information procurement, analysis, and validation. The whole process is cyclical, and steps repeat until the estimates are validated. The three steps are explained in detail below:

Information procurement: Information procurement is one of the most extensive and important stages in our research process, and quality data is critical for accurate analysis. We followed a multi-channel data collection process for antibiotics market to gather the most reliable and current information possible.

  • We buy access to paid databases such as Hoover’s and Factiva for company financials, industry information, white papers, industry journals, SME journals, and more.
  • We tap into Grand View’s proprietary database of data points and insights from active and archived monitoring and reporting.
  • We conduct primary research with industry experts through questionnaires and one-on-one phone interviews.
  • We pull from reliable secondary sources such as white papers and government statistics, published by organizations like WHO, NGOs, World Bank, etc., Key Opinion Leaders (KoL) publications, company filings, investor documents, and more.
  • We purchase and review investor analyst reports, broker reports, academic commentary, government quotes, and wealth management publications for insightful third-party perspectives.

Analysis: We mine the data collected to establish baselines for forecasting, identify trends and opportunities, gain insight into consumer demographics and drivers, and so much more. We utilized different methods of antibiotics market data depending on the type of information we’re trying to uncover in our research.

  • Market Research Efforts: Bottom-up Approach for estimating and forecasting demand size and opportunity, top-down Approach for new product forecasting and penetration, and combined approach of both Bottom-up and Top-down for full coverage analysis.

  • Value-Chain-Based Sizing & Forecasting: Supply-side estimates for understanding potential revenue through competitive benchmarking, forecasting, and penetration modeling.

  • Demand-side estimates for identifying parent and ancillary markets, segment modeling, and heuristic forecasting.

  • Qualitative Functional Deployment (QFD) Modelling for market share assessment.

Market formulation and validation: We mine the data collected to establish baselines for forecasting, identify trends and opportunities, gain insight into consumer demographics and drivers, and so much more. We utilize different methods of data analysis depending on the type of information we’re trying to uncover in our research.

  • Market Formulation: This step involves the finalization of market numbers. This step on an internal level is designed to manage outputs from the Data Analysis step.

  • Data Normalization: The final market estimates and forecasts are then aligned and sent to industry experts, in-panel quality control managers for validation.

  • This step also entails the finalization of the report scope and data representation pattern.

  • Validation: The process entails multiple levels of validation. All these steps run in parallel, and the study is forwarded for publishing only if all three levels render validated results.

Antibiotics Market Categorization:

The antibiotics market was categorized into four segments, namely drug (Cephalosporin, Penicillin, Fluoroquinolone, Macrolides, Carbapenems, Aminoglycosides, Sulfonamides, 7-ACA), type (Branded Antibiotics,Generic Antibiotics), action (Cell Wall Synthesis Inhibitors, Protein Synthesis Inhibitors, DNA Synthesis Inhibitors, RNA Synthesis Inhibitors, Mycolic Acid Inhibitors), and regions (North America, Europe, Asia Pacific, Latin America, Middle East & Africa).

Segment Market Methodology:

The antibiotics market was segmented into drug, type, action, and regions. The demand at a segment level was deduced using a funnel method. Concepts like the TAM, SAM, SOM, etc., were put into practice to understand the demand. We at GVR deploy three methods to deduce market estimates and determine forecasts. These methods are explained below:

Market research approaches: Bottom-up

  • Demand estimation of each product across countries/regions summed up to from the total market.

  • Variable analysis for demand forecast.

  • Demand estimation via analyzing paid database, and company financials either via annual reports or paid database.

  • Primary interviews for data revalidation and insight collection.

Market research approaches: Top-down

  • Used extensively for new product forecasting or analyzing penetration levels.

  • Tool used invoice product flow and penetration models Use of regression multi-variant analysis for forecasting Involves extensive use of paid and public databases.

  • Primary interviews and vendor-based primary research for variable impact analysis.

Market research approaches: Combined

  • This is the most common method. We apply concepts from both the top-down and bottom-up approaches to arrive at a viable conclusion.

Regional Market Methodology:

The antibiotics market was analyzed at a regional level. The globe was divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, keeping in focus variables like consumption patterns, export-import regulations, consumer expectations, etc. These regions were further divided into twenty-three countries, namely, the U.S.; Canada; UK; Germany; France; Italy; Spain; Denmark; Sweden; Norway; Japan; China; India; Australia; Thailand; South Korea; Brazil; Mexico; Argentina; South Africa; Saudi Arabia; UAE; Kuwait

All three above-mentioned market research methodologies were applied to arrive at regional-level conclusions. The regions were then summed up to form the global market.

Antibiotics market companies & financials:

The antibiotics market was analyzed via companies operating in the sector. Analyzing these companies and cross-referencing them to the demand equation helped us validate our assumptions and conclusions. Key market players analyzed include:

  • In May 2020, AbbVie completed acquisition of Allergan. AbbVie, Inc. was incorporated in 2013 and is headquartered in the U.S. It is a research-based pharmaceutical company, which is involved in discovering, developing, and marketing small-molecule drugs & biopharmaceuticals. The company was founded after separating from Abbott Laboratories. AbbVie is present in more than 175 countries, with both direct & indirect distributors and manufacturing facilities in various countries. The company supports treatment of chronic autoimmune diseases in oncology, virology, dermatology, gastroenterology, and rheumatology. It has 22 manufacturing facilities globally and employs 47,000 individuals globally.

  • Merck & Co., Inc. was incorporated in 1891 and is headquartered in the U.S. It is a global healthcare company involved in the development, discovery, manufacturing, and commercialization of prescription, branded, & over-the-counter vaccines, pharmaceuticals, and consumer care products for human & animal healthcare markets. The company offers healthcare solutions through vaccines, prescription medicines, biologic therapies, preventive and therapeutic agents, and animal health products. Some of the key customers of the company are wholesalers & retailers, hospitals, government agencies, managed healthcare providers, and veterinarians. Merck operates in more than 140 countries. As of December 2020, the company employed approximately 74,000 people globally.

  • Pfizer, Inc. is multinational American pharmaceutical company. It was incorporated in 1849 and is headquartered in New York, U.S. The company is involved in discovery, development, and manufacture of pharmaceutical products. Pfizer has a portfolio of vaccines and medicines. The company operates in 2 business segments: Essential Health (EH) and Innovative Health (IH). The Essential Health segment includes branded generics, biosimilars, infusion systems, generic sterile injectable products, and legacy brands. The Innovative Health segment works toward commercialization and development of medicines & vaccines. This segment operates in therapeutic segments: internal medicine, immunology, consumer healthcare, oncology, inflammation, rare diseases and vaccines. As of December 2019, Pfizer employed 88,300 individuals globally. It has 42 manufacturing facilities and operates in over 125 countries.

  • GlaxoSmithKline (GSK) is a healthcare company that develops, manufactures, and markets medicines, vaccines, & consumer healthcare products. The company history dates back to 1715, but in 2000, Glaxo Wellcome and SmithKline Beecham merged to form GlaxoSmithKline. GSK is headquartered in the UK. Its business is segmented into pharmaceuticals, vaccines, and consumer healthcare segments. Its pharmaceuticals segment offers therapeutics for CNS, cardiovascular conditions, respiratory disorders, dermatology, urogenital diseases, and others. In 2020, its R&D expenditure totaled USD 6.08 billion. The company employs over 99,000 people globally and has a presence in more than 100 countries, the majority of which are emerging economies.

  • Lupin Pharmaceuticals, Inc. is a global pharmaceutical company, headquartered in India, which offers a wide range of products, such as Active Pharmaceutical Ingredients (APIs), biotechnology products, branded & generic formulations, and specialty products. Lupin is one the major companies dealing in cardiovascular therapeutics, Non-Steroidal Anti-inflammatory Drugs (NSAIDS), anti-infectives, gastrointestinal drugs, Central Nervous System (CNS) therapeutics, asthma drugs, gynecology, diabetology, and pediatric medicines. It is one of the global leaders in cephalosporins and anti-tuberculosis segments. The company is present in around 100 countries with manufacturing facilities in India, Brazil, the U.S., the Netherlands, Germany, the UK, and Mexico. Lupin has more than 20,000 employees globally

  • Melinta Therapeutics is a commercial-stage company involved in the discovery, development, and commercialization of novel antibiotics for hospital and select non-hospital or community settings that address the need for effective treatment of drug-resistant Gram-negative and Grampositive infections. The company currently market four antibiotics, Baxdela, Vabomere, Orbactiv, and Minocin (for injection), with a few lead molecules in the pipeline. Melinta was established in October 2000 as a private company and is headquartered in New Jersey, U.S.

  • Novartis AG is involved in the R&D, manufacturing, and marketing of healthcare products. The company was formed by the merger between Sandoz Laboratories, Inc. and Ciba-Geigy AG. It is a publicly held organization and operates through three divisions: Innovative Medicines, Sandoz, and Alcon. The company’s Innovative Medicines division comprises oncology and pharmaceuticals business units. This division offers patented prescriptions and drugs in the fields of immunology, cardiology, respiratory medicine, dermatology, and neurology. Sandoz provides generic medicines, API formulations, and other biotechnology services, while Alcon offers ophthalmic surgical instruments, lenses, and other products related to ophthalmology. The company distributes its products in nearly 155 countries worldwide and has more than 120,000 employees.

  • Teva Pharmaceutical Industries Ltd. was established in 1901. The company primarily focuses on branded molecules, specialty medicines, APIs, generic drugs, and OTC products. Teva’s R&D areas are integrated into biologics, generic drugs, new chemical entity, personalized medicines, and technology. The company’s pipeline consists of drugs for CNS, pain, and respiratory conditions, among others. As of December 2020, the company had 40,216 employees around the world. Teva Pharmaceuticals is one of the major generic pharmaceutical companies in North America & Europe and continues to broaden its global presence by expanding its product offerings & pipeline.

  • Nabriva Therapeutics Plc is a commercial-stage biopharmaceutical company that develops antibiotics for the treatment of infectious diseases. Nabriva Therapeutics plc has wholly owned subsidiaries, such as Nabriva Therapeutics GmbH, Nabriva Therapeutics US, Inc., and Nabriva Therapeutics Ireland DAC. In 2006, it was formed as a separate business from Sandoz GmbH Antibiotics Research Institute (ABRI) in Vienna. The company is engaged in research, development, and commercialization of novel anti‐infective agents for serious infections. Nabriva has offices in the U.S., Ireland (Dublin), and Austria (Vienna).

  • Mylan N.V. was incorporated in 1961 and is headquartered in Pennsylvania, U.S. In November 2020, the merger of Mylan and Upjohn (Pfizer) resulted in the formation of Viatris. The merger was announced in July 2019. It is a global pharmaceutical company that discovers, develops, manufactures, and delivers generic, branded, API, biosimilar, & over-the-counter healthcare products for cardiovascular, CNS & anesthesia, diabetes & metabolism, gastroenterology, immunology, oncology, respiratory & allergy, infectious diseases, and women’s healthcare. The company operates in North America, Europe, and rest of world, wherein North America holds the largest revenue share, followed by Europe and rest of the world. Mylan operates in 165 countries and has 47 manufacturing facilities, out of which, 19 facilities are in India. Viatris’s business is segmented into 10 therapeutic areas: CNS & anesthesia, oncology, immunology, infectious diseases, cardiovascular, dermatology, respiratory & allergy, gastroenterology, diabetes & metabolism, and women’s healthcare.

Value chain-based sizing & forecasting

Supply Side Estimates

  • Company revenue estimation via referring to annual reports, investor presentations, and Hoover’s.

  • Segment revenue determination via variable analysis and penetration modeling.

  • Competitive benchmarking to identify market leaders and their collective revenue shares.

  • Forecasting via analyzing commercialization rates, pipelines, market initiatives, distribution networks, etc.

Demand side estimates

  • Identifying parent markets and ancillary markets

  • Segment penetration analysis to obtain pertinent

  • revenue/volume

  • Heuristic forecasting with the help of subject matter experts

  • Forecasting via variable analysis

Antibiotics Market Report Objectives:

  • Understanding market dynamics (in terms of drivers, restraints, & opportunities) in the countries.

  • Understanding trends & variables in the individual countries & their impact on growth and using analytical tools to provide high-level insights into the market dynamics and the associated growth pattern.

  • Understanding market estimates and forecasts (with the base year as 2022, historic information from 2018 - 2022, and forecast from 2024 to 2030). Regional estimates & forecasts for each category are available and are summed up to form the global market estimates.

Antibiotics Market Report Assumptions:

  • The report provides market value for the base year 2023 and a yearly forecast till 2030 in terms of revenue/volume or both. The market for each of the segment outlooks has been provided on region & country basis for the above-mentioned forecast period.

  • The key industry dynamics, major technological trends, and application markets are evaluated to understand their impact on the demand for the forecast period. The growth rates were estimated using correlation, regression, and time-series analysis.

  • We have used the bottom-up approach for market sizing, analyzing key regional markets, dynamics, & trends for various products and end-users. The total market has been estimated by integrating the country markets.

  • All market estimates and forecasts have been validated through primary interviews with the key industry participants.

  • Inflation has not been accounted for to estimate and forecast the market.

  • Numbers may not add up due to rounding off.

  • Europe consists of EU-8, Central & Eastern Europe, along with the Commonwealth of Independent States (CIS).

  • Asia Pacific includes South Asia, East Asia, Southeast Asia, and Oceania (Australia & New Zealand).

  • Latin America includes Central American countries and the South American continent

  • Middle East includes Western Asia (as assigned by the UN Statistics Division) and the African continent.

Primary Research

GVR strives to procure the latest and unique information for reports directly from industry experts, which gives it a competitive edge. Quality is of utmost importance to us, therefore every year we focus on increasing our experts’ panel. Primary interviews are one of the critical steps in identifying recent market trends and scenarios. This process enables us to justify and validate our market estimates and forecasts to our clients. With more than 8,000 reports in our database, we have connected with some key opinion leaders across various domains, including healthcare, technology, consumer goods, and the chemical sector. Our process starts with identifying the right platform for a particular type of report, i.e., emails, LinkedIn, seminars, or telephonic conversation, as every report is unique and requires a differentiated approach.

We send out questionnaires to different experts from various regions/ countries, which is dependent on the following factors:

  • Report/Market scope: If the market study is global, we send questionnaires to industry experts across various regions, including North America, Europe, Asia Pacific, Latin America, and MEA.

  • Market Penetration: If the market is driven by technological advancements, population density, disease prevalence, or other factors, we identify experts and send out questionnaires based on region or country dominance.

The time to start receiving responses from industry experts varies based on how niche or well-penetrated the market is. Our reports include a detailed chapter on the KoL opinion section, which helps our clients understand the perspective of experts already in the market space.

What questions do you have? Get quick response from our industry experts. Request a Free Consultation



This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.



We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

esomar icon

ESOMAR certified & member


ISO Certified

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.

great place to work icon